Influenza A virus H7N9 vaccine - EpiVax

Drug Profile

Influenza A virus H7N9 vaccine - EpiVax

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiVax
  • Developer EpiVax; Flinders University; Vaxine
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 18 Sep 2017 Epivax, the University of Massachusetts Medical School, Protein Sciences Corporation and the University of Georgia agree to co-develop influenza A H7N9 vaccine for Influenza-A virus H7N9 subtype
  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 18 Sep 2016 Phase-I clinical trials in Influenza-A virus H7N9 subtype in USA (Parenteral) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top